Recent Updates — DHR
Danaher reported third-quarter net earnings of $1.2 billion, or $1.71 per diluted share, a 34.5% increase year-over-year. Non-GAAP adjusted diluted EPS grew 11.5% to $2.11 on revenues that rose 8.5% to $6.6 billion. The company raised its full-year 2026 adjusted diluted net earnings per share guidance to a range of $8.57 to $8.62, up from the previous forecast of $8.45 to $8.60. Danaher is a leading global life sciences and diagnostics innovator.
The Danaher Corporation board increased its size to thirteen members and appointed Daniel L. Comas and Robert M. Hershberg as directors effective October 9, 2026. Mr. Comas is a former executive vice president and CFO who served as a senior advisor and consultant before his appointment. Dr. Hershberg brings extensive life sciences experience from roles at HilleVax, Celgene, and other biotech firms. Alan G. Spoon notified the company of his retirement from the board, effective at the 2027 annual meeting. Additionally, founders Steven and Mitchell Rales waived their rights to previously granted restricted stock units. Danaher operates in the technology and healthcare sectors, providing scientific instruments, diagnostics, and bioprocessing products.
Danaher Corporation appointed Julie Sawyer Montgomery as President and Chief Executive Officer effective October 1, 2026, succeeding Rainer M. Blair who will retire from executive roles but serve as Senior Advisor through March 31, 2027. Ms. Sawyer Montgomery’s compensation includes a $1.5 million annual base salary, a target cash incentive of 200% of base salary, and a $13.2 million long-term incentive award. She also received a special $20 million Long-Term Growth Award in the form of stock options vesting over five years. Mr. Blair will receive severance equivalent to 12 months of base salary plus target bonus upon his departure from employment on December 31, 2026. The Board also approved special equity grants for CFO Matthew Gugino ($12.5 million), Executive Vice President Christopher P. Riley ($8 million), and Chief Science Officer Jose-Carlos Gutierrez-Ramos ($2.625 million). Founders Steven and Mitchell Rales received options to purchase 1,000,000 shares and RSUs for 500,000 shares each. Danaher operates in the life sciences and diagnostics industry.
Danaher Corporation reported second quarter 2026 results with net earnings of $870 million, or $1.23 per diluted common share, representing a 60% year-over-year increase. Revenues rose 5.5% to $6.3 billion. Non-GAAP adjusted diluted net earnings per share grew 8.0% to $1.94. Operating cash flow reached $1.5 billion, while non-GAAP free cash flow was $1.3 billion. Following the earlier-than-anticipated completion of the Masimo acquisition, the company raised its full year 2026 adjusted diluted net earnings per share guidance to a range of $8.45 to $8.60. Danaher also announced its intention to acquire StatLab, a histology workflow manufacturer, by the end of 2026. Danaher is a global life sciences and diagnostics company.
Danaher Corporation and its subsidiary, DH Masi Finance Inc., entered into a note purchase agreement to issue seven series of senior notes with aggregate principal amounts totaling CHF 2,382,940,000. The notes feature interest rates ranging from 1.65% to 2.51% and maturities spanning from 2031 to 2056. The company intends to use the net proceeds for general corporate purposes, such as acquisitions and share repurchases.
Danaher Corporation shareholders approved the Amended and Restated Danaher Corporation Omnibus Incentive Plan at the company's annual meeting on May 5, 2026. The approved plan increases the company's share reserve by 20 million shares of common stock and extends the plan's term to May 5, 2036.